Key result
A tailored approach for heart failure pharmacotherapy during hospitalization and immediately after discharge could reduce early adverse events and prevent readmission.
Why the study?
Acute heart failure requiring hospitalisation is associated with poor prognosis and high 30-day readmission rates, highlighting the need for tailored in-hospital and early post-discharge pharmacotherapy to reduce early adverse events.
Optimizing guideline-directed medical therapy during hospitalization and early post-discharge is crucial to reduce the high rates of early rehospitalization in patients with acute decompensated heart failure.
Heart failure (HF) is a pandemic syndrome characterised by raised morbidity and mortality. An acute HF event requiring hospitalisation is associated with a poor prognosis, in both the short and the long term. Moreover, early rehospitalisation after discharge negatively affects HF management and survival rates. Cardiovascular and non-cardiovascular conditions combine to increase rates of HF hospital readmission at 30 days. A tailored approach for HF pharmacotherapy while the patient is in hospital and immediately after discharge could be useful in reducing early adverse events that cause rehospitalisation and, consequently, prevent worsening HF and readmission during the vulnerable phase after discharge.
No takes yet. Share an insight, caveat, or question.
Iacovoni et al. (2019) conducted a review in Acute Decompensated Heart Failure. Heart failure pharmacotherapy was evaluated. A tailored approach for heart failure pharmacotherapy during hospitalization and immediately after discharge could reduce early adverse events and prevent readmission.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: